

# Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa

Da Meng, Sara D. Ragi, and Stephen H. Tsang

Correspondence: [Sht2@cumc.columbia.edu](mailto:Sht2@cumc.columbia.edu)  
<https://doi.org/10.1016/j.ymthe.2022.06.007>

(Molecular Therapy 28, 2139–2149; October 2020)

In the originally published version of this article, it was stated that “The National Institute of Standards and Technology has set the limit for an acceptable CRISPR off-targeting rate in patients at 25%. [56–59]” This percentage is incorrect, so we have elected to redact it entirely from the review.

The authors regret this error.